# Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines

> **NCT03736928** · PHASE2 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 401 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **BIOLOGICAL:** AbobotulinumtoxinA dose level 1 or 2
- **OTHER:** placebo
- **BIOLOGICAL:** AbobotulinumtoxinA dose 3
- **BIOLOGICAL:** AbobotulinumtoxinA dose 4

## Key facts

- **NCT ID:** NCT03736928
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-26
- **Primary completion:** 2019-12-09
- **Final completion:** 2020-08-20
- **Target enrollment:** 401 (ACTUAL)
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03736928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03736928, "Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03736928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*